TaiMed Biologics Inc. (TPEX: 4147)
Taiwan
· Delayed Price · Currency is TWD 74.70
+0.80 (1.08%)
Oct 11, 2024, 1:30 PM CST
TaiMed Biologics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 641.66 | 491.78 | 563.01 | 413.44 | 722.49 | 704.5 | Upgrade
|
| Revenue Growth (YoY) | 7.11% | -12.65% | 36.18% | -42.78% | 2.55% | 192.28% | Upgrade
|
| Cost of Revenue | 369.08 | 266.54 | 347.3 | 329.49 | 311.77 | 474.49 | Upgrade
|
| Gross Profit | 272.57 | 225.23 | 215.71 | 83.96 | 410.71 | 230.01 | Upgrade
|
| Selling, General & Admin | 73.94 | 97.19 | 74.45 | 109.72 | 59.55 | 44.17 | Upgrade
|
| Research & Development | 306.73 | 294.28 | 333.12 | 460.6 | 394.45 | 575.83 | Upgrade
|
| Other Operating Expenses | - | - | - | - | 89.47 | - | Upgrade
|
| Operating Expenses | 380.66 | 391.46 | 407.57 | 570.32 | 543.47 | 620.01 | Upgrade
|
| Operating Income | -108.09 | -166.23 | -191.86 | -486.37 | -132.76 | -389.99 | Upgrade
|
| Interest Expense | -14.13 | -14.81 | -10.1 | -7.44 | -4.09 | -0.36 | Upgrade
|
| Interest & Investment Income | 18.16 | 8.36 | 4.34 | 4.03 | 8.48 | 14.73 | Upgrade
|
| Currency Exchange Gain (Loss) | 18.41 | 2.04 | 48.69 | -11.38 | 2.47 | 5.94 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.93 | 4.88 | 2.44 | 3.45 | 4.35 | 4.12 | Upgrade
|
| EBT Excluding Unusual Items | -80.73 | -165.76 | -146.48 | -497.7 | -121.55 | -365.56 | Upgrade
|
| Gain (Loss) on Sale of Investments | -26.58 | -29.05 | -122.81 | 26.76 | -63.13 | -213.09 | Upgrade
|
| Gain (Loss) on Sale of Assets | -2.42 | - | - | 0.01 | 1.37 | - | Upgrade
|
| Pretax Income | -109.74 | -194.81 | -269.29 | -470.93 | -183.3 | -578.65 | Upgrade
|
| Net Income | -109.74 | -194.81 | -269.29 | -470.93 | -183.3 | -578.65 | Upgrade
|
| Net Income to Common | -109.74 | -194.81 | -269.29 | -470.93 | -183.3 | -578.65 | Upgrade
|
| Shares Outstanding (Basic) | 258 | 253 | 252 | 252 | 252 | 252 | Upgrade
|
| Shares Outstanding (Diluted) | 258 | 253 | 252 | 252 | 252 | 252 | Upgrade
|
| Shares Change (YoY) | 2.22% | 0.18% | 0.04% | 0.03% | 0.07% | 0.52% | Upgrade
|
| EPS (Basic) | -0.43 | -0.77 | -1.07 | -1.87 | -0.73 | -2.30 | Upgrade
|
| EPS (Diluted) | -0.43 | -0.77 | -1.07 | -1.87 | -0.73 | -2.30 | Upgrade
|
| Free Cash Flow | 115.5 | -31.75 | -608.77 | -220.96 | -255.55 | -776.86 | Upgrade
|
| Free Cash Flow Per Share | 0.45 | -0.13 | -2.41 | -0.88 | -1.01 | -3.08 | Upgrade
|
| Gross Margin | 42.48% | 45.80% | 38.31% | 20.31% | 56.85% | 32.65% | Upgrade
|
| Operating Margin | -16.85% | -33.80% | -34.08% | -117.64% | -18.38% | -55.36% | Upgrade
|
| Profit Margin | -17.10% | -39.61% | -47.83% | -113.91% | -25.37% | -82.14% | Upgrade
|
| Free Cash Flow Margin | 18.00% | -6.46% | -108.13% | -53.44% | -35.37% | -110.27% | Upgrade
|
| EBITDA | 39.78 | -17.72 | -42.22 | -336.3 | 2.3 | -300.4 | Upgrade
|
| EBITDA Margin | 6.20% | -3.60% | -7.50% | -81.34% | 0.32% | -42.64% | Upgrade
|
| D&A For EBITDA | 147.87 | 148.51 | 149.64 | 150.07 | 135.06 | 89.59 | Upgrade
|
| EBIT | -108.09 | -166.23 | -191.86 | -486.37 | -132.76 | -389.99 | Upgrade
|
| EBIT Margin | -16.85% | -33.80% | -34.08% | -117.64% | -18.38% | -55.36% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.